The effects of the renin-angiotensin-aldosterone system blockers on serum ischemia-modified albumin levels in autosomal dominant polycystic kidney disease

Ermurat S., GÜLLÜLÜ M., SARANDÖL E.

IRISH JOURNAL OF MEDICAL SCIENCE, cilt.191, sa.6, ss.2777-2783, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 191 Sayı: 6
  • Basım Tarihi: 2022
  • Doi Numarası: 10.1007/s11845-022-02925-y
  • Dergi Adı: IRISH JOURNAL OF MEDICAL SCIENCE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Biotechnology Research Abstracts, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.2777-2783
  • Anahtar Kelimeler: Autosomal dominant polycystic kidney disease, Ischemia modified albumin, Oxidative stress, Renin-angiotensin-aldosterone blockade, OXIDATIVE STRESS, ENDOTHELIAL DYSFUNCTION, ASYMMETRIC DIMETHYLARGININE, INSULIN-RESISTANCE, PROGRESSION, BLOCKADE, DAMAGE
  • Bursa Uludağ Üniversitesi Adresli: Evet

Özet

Background Among one of the common hereditary causes of chronic kidney disease is autosomal-dominant polycystic kidney disease (ADPKD), and its incidence rate is reported as one between 500 and 1.000 individuals. The most common complications of ADPKD are hypertension (HT) and end-stage renal disease (ESRD). HT occurring in the early stage of ADPKD leads to deteriorations in renal function. Aims It was aimed to investigate the ischemia-modified albumin (IMA) levels and the effect of renin-angiotensin-aldosterone system (RAAS) blockers on serum IMA levels in patients with ADPKD. Methods One hundred and fifteen patients were included as ADPKD (n = 50), HT (n = 35), and healthy control (HC) groups (n = 30). Patients with ADPKD and HT were divided into two subgroups as RAAS blocker-users and non-users. Results Serum IMA levels were detected as 0.42 (0.17-0.80) in ADPKD and 0.28 (0.04-0.51) in HT and 0.36 (0.22-0.56) in HC groups as absorbance units (ABSU), and the highest serum IMA level was seen in Group ADPKD. Serum IMA levels were 0.33 +/- 0.14 in RAAS blocker-users and 0.41 +/- 0.11 ABSU in non-users with ADPKD. Serum IMA levels were witnessed to be significantly lower in RAAS blocker-users in Groups ADPKD (p = 0.038) and HT (p = 0.004), compared to non-users. Given basal and 6-month values of those with ADPKD, the levels of serum IMA within 6 months were significantly lower (p = 0.002). Conclusions We consider that serum IM levels should be assessed in oxidative stress (OS)-related conditions, such as ADPKD, and RAAS blockers may be effective in reducing serum IMA levels in ADPKD and HT patients.